New study aims to catch eye cancer spread early with blood tests and scans
NCT ID NCT04424719
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study follows 700 people with uveal melanoma, a rare eye cancer, who are at high risk of the cancer spreading to the liver. Participants get regular liver MRIs and blood tests to look for early signs of metastasis. The goal is to see if personalized monitoring can detect relapses sooner.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to earlier detection of liver metastases in uveal melanoma patients, improving treatment timing.
- What could go wrong
- This is an observational study, not testing a new treatment. It may not change outcomes directly, and early detection does not guarantee better survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Curie
RECRUITINGParis, 75005, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug tame advanced solid tumors?
- Can a single eye injection shrink melanoma and save sight?
- Supercharged immune cells take aim at childhood cancers
- Can a pill prevent eye cancer spread? new trial aims to find out
- New drug shows promise in shrinking eye cancer before surgery